

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT8166422

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
SERGIO QUEZADA	11/21/2019
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	UNIVERSITY COLLEGE LONDON
<b>Street Address:</b>	GOWER STREET
<b>City:</b>	LONDON
<b>State/Country:</b>	UNITED KINGDOM
<b>Postal Code:</b>	WC1E 6BT
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	16782440
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(617)502-5002
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	6172485000
<b>Email:</b>	patentdocket@choate.com
<b>Correspondent Name:</b>	CHOATE HALL & STEWART LLP
<b>Address Line 1:</b>	TWO INTERNATIONAL PLACE
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02110
<b>ATTORNEY DOCKET NUMBER:</b>	2003882-0078
<b>NAME OF SUBMITTER:</b>	AARON J. OGDEN
<b>SIGNATURE:</b>	/Aaron J. Ogden/
<b>DATE SIGNED:</b>	09/14/2023
<b>Total Attachments: 18</b>	
source=Assignment (Quezada to UCL) as filed#page1.tif	
source=Assignment (Quezada to UCL) as filed#page2.tif	
source=Assignment (Quezada to UCL) as filed#page3.tif	
source=Assignment (Quezada to UCL) as filed#page4.tif	
source=Assignment (Quezada to UCL) as filed#page5.tif	
source=Assignment (Quezada to UCL) as filed#page6.tif	

source=Assignment (Quezada to UCL) as filed#page7.tif  
source=Assignment (Quezada to UCL) as filed#page8.tif  
source=Assignment (Quezada to UCL) as filed#page9.tif  
source=Assignment (Quezada to UCL) as filed#page10.tif  
source=Assignment (Quezada to UCL) as filed#page11.tif  
source=Assignment (Quezada to UCL) as filed#page12.tif  
source=Assignment (Quezada to UCL) as filed#page13.tif  
source=Assignment (Quezada to UCL) as filed#page14.tif  
source=Assignment (Quezada to UCL) as filed#page15.tif  
source=Assignment (Quezada to UCL) as filed#page16.tif  
source=Assignment (Quezada to UCL) as filed#page17.tif  
source=Addendum to Assignment#page1.tif

## COMBINED JOINT ASSIGNMENT & DECLARATION

### ASSIGNMENT

WHEREAS, each of the individuals (the “**Inventors**”) named in the below Table 1 resides in the City, State, and Country listed in Table 1, is named as an inventor on one or more of the patent filings listed on **Schedule A** (the “**Patent Filings**”), each is aware of the **Patent Filings**, and, during the entire time of his/her contribution to the invention(s) (the “**Inventions**”) described in the **Patent Filings** was obligated to assign his or her rights to an entity as described further below:

<b>Inventor Name</b>	<b>City, State, Country</b>
<b>1. Anne Goubier</b>	Hertfordshire, GB
<b>2. Beatriz Goyenechea Corzo</b>	Hertfordshire, GB
<b>3. Josephine Salimu</b>	Hertfordshire, GB
<b>4. Kevin Moulder</b>	Hertfordshire, GB
<b>5. Pascal Merchiers</b>	Hertfordshire, GB
<b>6. Mark Brown</b>	Hertfordshire, GB
<b>7. Sergio Quezada</b>	London, GB
<b>8. James Geoghegan</b>	Lyme, NH, US
<b>9. Bianka Prinz</b>	Lebanon, NH, US

Table 1

### I. RECITALS

WHEREAS, the **Patent Filings** describe certain antibodies (and related uses) developed pursuant to a First Amended and Restated Collaboration Agreement (the “Collaboration Agreement”) dated November 25, 2015 between **ADIMAB LLC**, (hereinafter “**ADIMAB**”), having a usual place of business at 7 Lucent Drive Lebanon, NH 03766, U.S. and **Tusk Therapeutics Ltd.**, 6 Falcon Way, Shire Park, Welwyn Garden City, Hertfordshire AL7 1TW, UK (f.k.a. STAB; hereinafter “**TUSK**”);

WHEREAS Section 5.1 of the Collaboration Agreement states that “**ADIMAB** shall solely own, regardless of inventorship, all Program Patents directed to Adimab Platform Technology Improvements and, prior to Option exercise, all Program Antibody Patents”;

WHEREAS Section 3.2(a) of the Collaboration Agreement provides that “Adimab hereby grants [TUSK] the exclusive option (each, an “Option”) to obtain the licenses of Section 3.2(b) (Development and Commercialization License and Assignment) for Optioned Antibodies discovered during a Research Program as well as all Program-Benefited Antibodies”; and Section 3.2(b) of the Collaboration Agreement provides that “Adimab hereby, effective on [TUSK]’s exercise of the Option assigns to [TUSK], subject to the terms and conditions of this Agreement, all right, title and interest in and to the Optioned Program Antibody Patents.”

WHEREAS each of **James Geoghegan** and **Bianka Prinz** was an employee of **ADIMAB** during the entire time of his or her contribution to the Inventions and the Patent

Filings, and, in consideration of his or her employment, had agreed to assign and had assigned to **ADIMAB** or to any person or entity designated by **ADIMAB** his or her entire right, title and interest in the Inventions and the Patent Filings; WHEREAS **Pascal Merchiers** was a consultant to TUSK during the entire time of his contribution to the Inventions and the Patent Filings and, pursuant to an Acknowledgement, Assignment and Understating dated May 3<sup>rd</sup>, 2018 had agreed to assign and had assigned to **TUSK** or to any person or entity designated by **TUSK** his entire right, title and interest in the Inventions and the Patent Filings; and pursuant to Section 5.1 of the Collaboration Agreement **ADIMAB** solely owned, “regardless of inventorship, all Program Patents directed to Adimab Platform Technology Improvements and, prior to Option exercise, all Program Antibody Patents”

WHEREAS **Sergio Quezada** was an employee of the **University College London**, of Gower Street, London, WC1E 6BT, UK (hereinafter “**UCL**”) during the entire time of his contribution to the Inventions and the Patent Filings and, pursuant to an Acknowledgement and Undertaking dated May 16<sup>th</sup>, 2018 had assigned to **UCL** or to any person or entity designated by **UCL** all right, title and interest in the Inventions and the Patent Filings;

WHEREAS **Cancer Research Technology** Limited (hereinafter “**CRT**”) is a company registered in England and Wales under 1626049 with registered office at Angel Building 407 St. John Street London, EC1V 4AD, UK that often enters into agreements with **UCL** to commercialize certain technologies developed at **UCL**, which agreements typically include an assignment from **UCL** to **CRT**; and further whereas, in light of the circumstances under which the Inventions were developed, **CRT** and **UCL** entered into an Assignment and Agreement dated Jun 15<sup>th</sup>, 2018 with each other and furthermore with **TUSK** whereby **UCL**’s entire right, title and interest in the Inventions was jointly assigned to **CRT** and **TUSK**; .

WHEREAS each of **Anne Goubier**; **Beatriz Goyenechea Corzo**; **Josephine Salimu**; **Kevin Moulder**; **Mark Brown** was an employee of **TUSK** during the entire time of his contribution to the Inventions and the Patent Filings and in consideration of his or her employment, had agreed to assign and had assigned to **TUSK** or to any person or entity designated by **TUSK** all right, title and interest in the Inventions and the Patent Filings;

WHEREAS, **TUSK** has provided to **ADIMAB** payment and written notice of its exercise of the Option detailed in Sections 3.2(a) and 3.2(b) of the Collaboration Agreement and **ADIMAB** has confirmed receipt thereby operating to assign **ADIMAB**’s entire right title and interest to **TUSK**

NOW, THEREFORE, the present document operates to confirm the facts above, and moreover to confirm that, via the relationships and agreements above, all right title and interest in the Inventions and Patent Filings is vested in **TUSK** and **CRT** (the “**ASSIGNEES**”)

## **CONFIRMATION**

In particular, each of the undersigned hereby confirms that the above RECITALS set forth an accurate recitation of the various agreements pursuant to which his or her entire right, title and interest in and to the Inventions and the Patent Filings, in consideration of good and

valuable consideration the receipt of which is hereby acknowledged, has been sold, assigned, and transferred unto one or both of said ASSIGNEES, and their successors, assigns and legal representatives;

Furthermore, each of the undersigned hereby agrees that, to the extent that any transfer documented in the agreements described in the RECITALS may not have fully effected transfer, s/he hereby sells, assigns, and transfers his/her entire right, title, and interest in the Inventions and the Patent Filings into the ASSIGNEES in accordance with the transfers set forth above.

Thus, the present agreement documents that the ASSIGNEES are the proper and present owners of the entire right, title and interest in the Inventions and the Patent Filings throughout the United States of America, its territories and all foreign countries, including in and to any priority applications included in the Patent Filings and/or to which any of the Patent Filings claims priority, and specifically including any right of priority thereto;

Each of the undersigned hereby furthermore confirms that his or her sale, assignment and transfer applies to any and all Patent Filings currently listed in Schedule A, and also to any application that is based in whole or in part on one or more such Patent Filings, including to divisional, continuing, substitute, renewal, reissue, reexamination and other applications, for example that claim priority to one or more Patent Filings or otherwise describe and claim an Invention.

Still further, each of the undersigned hereby confirms and agrees that his/her sale, assignment and transfer pertains to any and all rights in the Invention(s) or the Patent Filings, arising under or pursuant to any and all international agreements, treaties, or laws relating to the protection of industrial property, including all rights of priority under the International Convention for the Protection of Industrial Property, and in and to any such patent(s) as may issue thereon including any and all original and reissued patents which have been or shall be issued in the United States and any foreign countries; said inventions, applications, and patent(s) to be held and enjoyed by ASSIGNEES for their own use and for the use of their respective successors, assigns and legal representatives, to the full end of the term for which said patent(s) may be granted as fully and entirely as the same would have been held by him or her had this sale, assignment and transfer not been made;

AND, each of the undersigned hereby acknowledges that this Assignment, being of the entire right, title, and interest in and to the Inventions or the Patent Filings, carries with it the right in ASSIGNEES, by attorneys and agents of ASSIGNEES' selection, to apply for and receive any and all patent(s) for said Inventions in its own name;

AND, each of the undersigned hereby further agrees for him/herself and his or her executors and administrators to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the patent(s) to ASSIGNEES and their respective successors, assignees and legal representatives, but at their expense and charges, including the execution of application for patents in any foreign countries, the execution of substitution, reissue, divisional or continuation applications, and the giving of testimony, preliminary statements, or other statements in any interference or other proceeding in which the inventions or any applications or patents directed to the inventions may be involved by

communicating to the ASSIGNEES all facts he or she knows relating to the inventions and their history, and generally by doing everything possible which ASSIGNEES shall consider desirable for aiding in securing and maintaining proper patent protection for the inventions and for vesting title in the inventions and all applications for patent and all patents on the inventions in ASSIGNEES;

AND, each of the undersigned hereby appoints each ASSIGNEE as his or her common agent for purposes of prosecuting international patent applications and any national patent applications for which such common agency is recognized;

AND, each of the undersigned hereby requests the Commissioner for Patents of the United States Patent and Trademark Office to issue any and all patent(s) as shall be granted upon said application or applications based thereon to ASSIGNEES and their respective successors, assigns, and legal representatives;

AND, each of the undersigned covenants with said ASSIGNEES that no assignment, grant, mortgage, license, or other agreement affecting the rights and property herein conveyed has been made to others by him or her, and that full right to convey the same as herein expressed is possessed by me.

Name: Anne Goubier

Date

7/10/2019

Witness Signature:

M. Laleg

Name (please print): MARIANNE MULDREDA

Date

7/10/19


Witness Signature:

A. E. Tonge


Name (please print): DEBORAH TONGE

Date

7/10/2019


  
Name: Beatriz Goyenechea Corzo

3.10.2019  
Date

Witness Signature: 

MARCO BARDELLI  
Name (please print):


03/10/2019  
Date

Witness Signature: 

LAURA EVANS  
Name (please print):

03/10/2019  
Date



  
Name: **Josephine Salimu**


09/10/2019  
Date

Witness Signature:


  
Name (please print): **MARIA TERESA RODRIGUEZ PLATA**

09/10/2019  
Date


Witness Signature:

  
Name (please print): **MARK ADRIAN BROWN**


09/10/2019  
Date

  
Name: **Kevin Moulder**


3/10/2019  
Date

Witness Signature:   
LAURA EVANS  
Name (please print):

03/10/2019  
Date


Witness Signature:   
MARCO BARNELL  
Name (please print):

03/10/2019  
Date

  
Name: Pascal Merchiers


06 OCT 2019  
Date

Witness Signature:


  
Name (please print): BRAM MERCHIERS

06 OCT 2019  
Date

Witness Signature:

  
Name (please print): KATRIEN EGGERS

6 OCT 2019  
Date


  
Name: Mark Brown

7/10/2019  
Date

Witness Signature: 


MARIANNE MULDER  
Name (please print):

7/10/19  
Date

Witness Signature: 

DEBORAH TONGE  
Name (please print):

7/10/2019  
Date

  
Name: **Sergio Quezada**

\_\_\_\_\_  
Date

Witness Signature:

\_\_\_\_\_  
Name (please print):

\_\_\_\_\_  
Date

Witness Signature:

\_\_\_\_\_  
Name (please print):

\_\_\_\_\_  
Date

James Geoghegan  
Name: James Geoghegan

10/8/2019  
Date

Witness Signature: Ross Connor

Ross Connor  
Name (please print):

10/8/19  
Date

Witness Signature:

Katy J. Newland  
Name (please print): Katy J. Newland

10/8/19  
Date

Bianka Prinz  
Name: **Bianka Prinz**

10/8/19  
Date

Witness Signature:

Ross Connor  
Name (please print): **Ross Connor**

10/8/19  
Date

Witness Signature:

Katy J. Newland  
Name (please print): **Katy J. Newland**

10/8/19  
Date

Date \_\_\_\_\_

Title: Finance and Corporate Services Director



Understood and agreed to on behalf of Cancer Research Technology Limited

By: Angus Laidler

28th October 2019  
Date

Name: ANGUS LAIDLER  
(please print)

Title: Associate Director

Understood and agreed to on behalf of Adimab, LLC

By: 

Oct 8, 2019  
Date

Name: ERIC KRAULAND  
(please print)

Title: GR6F SCIENTIFIC OFFICER

**Schedule A**

<b>K&amp;S Reference</b>	<b>TUSK Reference</b>	<b>Adimab Reference</b>	<b>Choate Reference</b>	<b>Application No.</b>
P115237US	TSK031001 / a-634	aCD25-a-634	2003882-0068	62/642,218
P115238US	TSK031003 / a-674	aCD25-a-674	2003882-0069	62/642,230
P115240US	TSK031015 / a-646	aCD25-a-646	2003882-0070	62/642,232
P115241US	TSK031041 / a-672	aCD25-a-672	2003882-0071	62/642,243
P115242US	TSK031044 / a-686	aCD25-a-686	2003882-0072	62/642,248
				PCT/EP18/56312
U115238US	TSK031003 / a-674		2003882-0073	16/352,703
U115240US	TSK031015 / a-646		2003882-0074	16/352,709
U115242US	TSK031044 / a-686		2003882-0075	16/352,717
				GB1804027.9
				GB1804028.7
				GB1804029.5


### CONFIRMATION OF ASSIGNEE NAME

1. SCOTT DAVIS, declare as follows:
1. I am the Company Secretary and authorized to act as a signatory on behalf of Tusk Therapeutics, Ltd., a private company incorporated on December 16th, 2015, having its registered office in England and Wales, Company Number 09918170 ("Tusk"), who is an assignee and applicant of the patent applications listed below.
2. As to that certain Combined Joint Assignment & Declaration ("Assignment") executed by Tusk on May 6th, 2020 and by the persons listed as Inventors on the date indicated in the following table:

Inventor Name	City, State, Country	Date of Execution
Anne Goubier	Hertfordshire, GB	Oct. 7, 2019
Beatriz Goyenechea Corzo	Hertfordshire, GB	Oct. 3, 2019
Josephine Salinas	Hertfordshire, GB	Oct. 9, 2019
Kevin Moulder	Hertfordshire, GB	Oct. 3, 2019
Pascal Merchiers	Hertfordshire, GB	Oct. 6, 2019
Mark Brown	Hertfordshire, GB	Oct. 7, 2019
Sergio Quezada	London, GB	Oct. 29, 2019
James Geoghegan	Lyme, NH, US	Oct. 8, 2019
Bianka Prinz	Lebanon, NH, US	Oct. 8, 2019

Tusk is referred to on page 1 as "Tusk Therapeutics Ltd., 6 Falcon Way, Shire Park, Welwyn Garden City, Hertfordshire AL7 1TW, UK", and on page 14 as "Tusk Therapeutics Inc."

3. This declaration is presented for the purpose of confirming that the correct name of Tusk as party to the Assignment is **Tusk Therapeutics Ltd.**; and that any reference to "Tusk Therapeutics Inc." was a clerical error, the intent of which was to name Tusk Therapeutics Ltd.
4. I, Scott Davis, declare that all statements made herein of my own knowledge are true and that those statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful, false statements and the like are made punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code and that such willful, false statements may jeopardize the validity of the application or any patents that may issue thereon.

  
Signature, Signatory's Title, Tusk Therapeutics Ltd.

SCOTT DAVIS

Company Secretary

16 May 2023  
Date